DelveInsight’s “Primary Myelofibrosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Primary Myelofibrosis, historical and forecasted epidemiology as well as the Primary Myelofibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Primary Myelofibrosis Overview
Primary Myelofibrosis is a rare disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. It is classified as a type of chronic leukemia and belongs to a group of blood disorders called myeloproliferative diseases. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibers on which the stem cells can divide and grow. Specialized cells in the bone marrow, known as fibroblasts, make these fibers. Myelofibrosis can be of two types primary myelofibrosis and secondary myelofibrosis. Due to a shortage of red blood cells, myelofibrosis symptoms include extreme tiredness (fatigue) or shortness of breath, whereas the loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.
Primary Myelofibrosis Epidemiology Insights
In the countries of the European Union, the incidence of myelofibrosis ranges from a low of 0.3 per 100,000 persons to a high of 1.9 per 100,000 persons, with an average incidence of 1.1 per 100,000 persons.
In Olmsted County, Minnesota, USA, the annual incidence of primary myelofibrosis (PMF) is 1.33 per 100,000.
The prevalence of myelofibrosis is approximately 1 per 100,000 individuals worldwide.
In developed countries, the prevalence of myelofibrosis ranges from 0.5 per 100,000 per year to 9 per 100,000 per year.
Myelofibrosis is a disease that tends to affect the middle-aged and elderly population. The mean age at diagnosis is 60 years.
Click here to learn more about the Primary Myelofibrosis Market Landscape
The Report Covers the Primary Myelofibrosis Epidemiology Segmented by:
Total Primary Myelofibrosis incident cases
Total Primary Myelofibrosis diagnosed cases
Total Primary Myelofibrosis prevalent cases
Total Primary Myelofibrosis treatment cases
Primary Myelofibrosis Market Outlook
The Primary Myelofibrosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Primary Myelofibrosis market trends by analyzing the impact of current Primary Myelofibrosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Primary Myelofibrosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Primary Myelofibrosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Primary Myelofibrosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Companies Working in the Primary Myelofibrosis Market
Novartis
CTI Biopharmaceuticals
AbbVie
Bristol Myers Squibb
Galecto Bio AB
And many others
Primary Myelofibrosis Therapies Covered and Analyzed in the Report:
INC424
BKM120
Ruxolitinib
Pacritinib
PXS-5505
Learn more about the Key Companies and Emerging Therapies in the Primary Myelofibrosis Market
Table of Contents
Key Insights
Primary Myelofibrosis Introduction
Executive Summary of Primary Myelofibrosis
Disease Background and Overview
Epidemiology and patient population
Primary Myelofibrosis Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Primary Myelofibrosis Market Outlook
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting